Maturitas

Body mass index and sleep in women aged 40 to 64 years
pp. 1-8(8)
Authors: Asplund R.; &unknown;9berg H.E.

A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density
pp. 9-12(4)
Authors: Suzuki N.; Yano T.; Nakazawa N.; Yoshikawa H.; Taketani Y.

Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT)
pp. 13-23(11)
Authors: McCarthy T.; Dramusic V.; Carter R.; Costales A.; Ratnam S.S.

Transdermal hormonal replacement therapy with transdermal progestin every second month
pp. 25-30(6)
Authors: Lindgren R.; Risberg B.; Hammar M.; Berg G.

The endometrial nucleolar channel system as an indicator of progestin potency in HRT
pp. 31-36(6)
Authors: Ryder T.A.; Mobberley M.A.; Whitehead M.I.

Microscopic findings of the nail-fold capillaries -- dependence on menopausal status and hormone replacement therapy
pp. 37-46(10)
Authors: Haenggi W.; Linder H.R.; Birkhaeuser M.H.; Schneider H.

Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device
pp. 47-53(7)
Authors: Raudaskoski T.H.; Tomas E.I.; Paakkari I.A.; Kauppila A.J.; Laatikainen T.J.

Does vitamin D₃ have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D₃
pp. 55-61(7)
Authors: Tuppurainen M.; Heikkinen A.-M.; Penttila I.; Saarikoski S.

Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)
pp. 63-63(1)
Authors: Voigt L.F.; Deng Q.; Weiss N.S.

Hormonal management of the sick menopausal woman
pp. 63-63(1)
Author: Berga S.L.

Male osteoporosis
pp. 63-63(1)
Authors: Legrand E.; Le Levier F.; Chappard D.; Audran M.

Hormone substitution in patients treated for breast cancer
pp. 64-64(1)
Author: Wile A.

The risk for breast cancer: Various forms of hormone substitution therapy inducing different effects on important biological parameters
pp. 64-64(1)
Authors: Campagnoli C.; Biglia N.; Lesca L.; Sandri A.; Peris C.; Altare F.

Screening for ovarian cancer
pp. 64-64(1)
Authors: Carlson K.J.; Skates S.J.; Singer D.E.

The incidence of vaginal bleeding with tibolone treatment
pp. 64-65(2)
Authors: Rymer J.; Fogelman I.; Chapman M.G.

Ovarian function, therapy- oriented definition of menopause and climacteric
pp. 65-65(1)
Author: Utian W.H.

Menopause: An evolutionary perspective
pp. 65-65(1)
Author: Austad S.N.

The evolution of ovarian oocyte decline with aging and possible relationships to Down syndrome and Alzheimer disease
pp. 65-65(1)
Author: Finch C.E.

Ethical principles in the conduct of menopause research
pp. 66-66(1)
Author: Macklin R.

Estrogen deficiency and risk of Alzheimer's disease in women
pp. 66-66(1)
Authors: Paganini-Hill A.; Henderson V.W.

Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
pp. 66-66(1)
Authors: Brenner D.E.; Kukull W.A.; Stergachis A.; Van Belle G.; Bowen J.D.; McCormick W.C.; Teri L.; Larson E.B.

The menopause: When it is all over or is it?
pp. 66-66(1)
Author: Burger H.G.